Back to Stakeholders
Lead program: Phase I
Categories

2 domains / 4 areas / 2 specializations

Research, Drug Development & Manufacturing
Company-Led Drug Development & CommercializationClinical Research & Pipeline Products
Research, Drug Development & Manufacturing
Adjunct Industries
Adjunct Industries
Technology, Data, & Software PlatformsArtificial Intelligence

Mindstate Design Labs

Data updated

1 Drug Candidate

Clinical-stage AI neuroengineering platform company focused on designing psychoactive effect profiles and developing next-generation neuropsychiatric programs with psychedelic relevance.

Technology, Data, & Software Snapshot

Artificial Intelligence

Platform Model

AI / ML Platform

Deployment

Research / Managed Service

Geography

National

Coverage

1 country

Customer Types

Drug DevelopersResearch Organizations

Capability Focus Areas

Predictive ModelingProtocol / Decision Support

Data Modalities

Behavioral / Survey DataMixed Modalities

Technology Notes

Mindstate describes Osmanthus as an AI-powered neuroengineering platform based on psychoactive datasets and positions the company directly in psychedelic and related neuropsychiatric development.

Verification

Verified

Psychedelic Focus

Explicit Psychedelic Focus

Engagement Status

Active

Last Verified

Apr 9, 2026

Primary Platform Link

Source Evidence

Mindstate Design Labs - Homepage

https://www.mindstate.design/

Mindstate Press Release - Topline MSD-001 Clinical Trial Results

https://www.mindstate.design/press-releases/topline-study-msd-001-clinical-trial-results-and-lead-fixed-dose-combination-program-announcement

Pipeline Intelligence

Developer Momentum

Programme tracker
Active candidates
1

All tracked candidates active

Active programmes
1

All tracked programmes active

Lead stage
Phase I

Current furthest stage

Forecast coverage
1 of 1

1 active programme with forecast fields

Latest sourced update

Mindstate Design Labs Pipeline - MSD-001

Jun 26, 2026 - company-website - Mindstate Design Labs - MSD-001 (5-MeO-MiPT)

Next known catalyst

Phase I started

Q1 2027 - MSD-001 (5-MeO-MiPT) / MSD-001 Phase 1 Programme (Mood/Anxiety) — CHDR Netherlands - Confidence: 45%

3 sources0 pipeline-linked trials0 pipeline-linked papers

Development Programmes

1

MSD-001 (5-MeO-MiPT)

Phase I
Major Depressive Disorder (MDD)

Mood and anxiety disorders

Programme Tracker

Major Depressive Disorder (MDD)

Primary: EU (EMA)
Phase IActive

Forecast

Phase I started - Likely: Q1 2027

MSD-001 Phase 1 SAD study NCT06702332 is completed. Mindstate announced topline results on 2025-09-24: MSD-001 was safe and well tolerated, showed dose-proportional linear PK, produced narrowly defined psychoactive effects without hallucinations, and will primarily serve as a base compound for fixed-dose combinations. The next watch item is initiation or registration of a fixed-dose combination Phase 1 study.

Milestones

Funding milestone

Completed

Actual: Feb 1, 2022

$11.5M seed funding

Why it matters: Backed by Y Combinator, Initialized Capital, and founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, and Twitch. Unusually strong Silicon Valley backing for a psychedelic biotech.

Mindstate Announces Topline MSD-001 Results and Fixed-Dose Combination Programme(Press release)[Verified]Mindstate Design Labs Pipeline - MSD-001(company-website)[Verified]

regulatory-designation

Completed

Actual: Sep 1, 2024

FDA clearance granted to begin human testing of MSD-001

Why it matters: FDA clearance for 5-MeO-MiPT is notable because the DEA attempted to schedule this compound in January 2022 but withdrew the proposal in July 2022. The regulatory path was uncertain — FDA clearance confirms the compound can proceed clinically.

ClinicalTrials.gov NCT06702332 - MSD-001 Phase 1 SAD study(clinical-trial-registry)[Verified]

Funding milestone

Completed

Actual: Nov 1, 2024

$12.7M Series A raised (total funding ~$24.3M across 3 rounds)

Why it matters: Well-capitalized for continued clinical development. $24M total positions Mindstate for Phase 1 combination trials and potentially Phase 2.

Mindstate Announces Topline MSD-001 Results and Fixed-Dose Combination Programme(Press release)[Verified]Mindstate Design Labs Pipeline - MSD-001(company-website)[Verified]

phase-1-results

Completed

Actual: Sep 24, 2025

Topline Phase 1 results announced: 52 participants (47 evaluable) at CHDR Netherlands. MSD-001 produced strong but narrow psychoactive effects — heightened emotion, associative thinking, enhanced imagination — without hallucinations or ego dissolution. Scored markedly lower on all seven non-visual Altered States of Consciousness scale dimensions vs classical psychedelics. Dose-proportional linear PK. Safe and well-tolerated.

Why it matters: MSD-001 represents a new paradigm: "designed psychedelic experiences" with specific emotional/cognitive effects without the overwhelming perceptual distortion of classical psychedelics. The Osmanthus AI platform (70,000+ trip reports, 600+ effects) predicted this profile. EEG showed engagement of similar neural pathways as classic psychedelics despite the subjectively milder experience — suggesting neuroplasticity without hallucinatory intensity. This could make psychedelic therapy more accessible and scalable.

Mindstate reports MSD-001 Phase 1 topline results and fixed-dose combination strategy(Press release)[Verified]

Company milestone

Completed

Actual: Sep 24, 2025

Fixed-dose combination programme announced: MSD-001 + undisclosed compound combining serotonergic + adrenergic targets for anxiolytic effects, enhanced insight, and aesthetic perception ("tranquil insightful beauty")

Why it matters: Moving beyond single-compound psychedelics to rationally designed combinations is unprecedented. The combination targets a specific experiential profile that Osmanthus AI predicted would optimize therapeutic outcomes. Phase 1 of the combination planned.

Watch next: Fixed-dose combination Phase 1 initiation; indication-specific Phase 2 trial design; partnership announcements

Mindstate reports MSD-001 Phase 1 topline results and fixed-dose combination strategy(Press release)[Verified]

Recorded Events

Sep 24, 2025: phase-1-results

Sep 24, 2025: Company milestone

Nov 1, 2024: Funding milestone

Sep 1, 2024: regulatory-designation

Feb 1, 2022: Funding milestone

Evidence Links

ClinicalTrials.gov NCT06702332 - Single Ascending Dose Study of MSD-001

clinical-trial-registry - ClinicalTrials.gov - Sep 16, 2025 - Verified

ClinicalTrials.gov lists NCT06702332 as completed, with actual study completion 2025-07-11 and last update posted 2025-09-16.

Mindstate Announces Topline MSD-001 Results and Fixed-Dose Combination Programme

Press release - Mindstate Design Labs - Sep 24, 2025 - Verified

Company reported first-in-human Phase 1 results for MSD-001 and announced a lead fixed-dose combination programme.

Mindstate Design Labs Pipeline - MSD-001

company-website - Mindstate Design Labs - Jun 26, 2026 - Verified

Company site describes MSD-001 as the lead asset and as the base ingredient for multiple combination programmes.

Similar Developers

Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.

View landscape
Lophora
Phase I2 active candidates
same indication: Major Depressive Disorder (MDD)Phase I peersame regulator: EU EMAsimilar active pipeline size
Neurala Biosciences
Phase I2 active candidates
same indication: Major Depressive Disorder (MDD)Phase I peersimilar active pipeline sizeboth have forecast coverage
Arcadia Medicine
Phase I3 active candidates
same indication: Major Depressive Disorder (MDD)Phase I peerboth have forecast coverageboth have source coverage
Terran Biosciences
Phase I3 active candidates
same indication: Major Depressive Disorder (MDD)Phase I peerboth have forecast coverageboth have source coverage

Quick Facts

Type
Private Biotech
Founded
2022
Lead Stage
Phase I
Website
Visit